Albumin Assisted Diuresis in Patients with Cirrhosis and Ascites
Recruiting · Phase 2 · NCT06812390
Conditions: Cirrhosis, Ascites Hepatic
At a glance
- Research payments reported, 2025
- $1,324
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Anahita Rabiee MD MHS (with Grifols Shared Services North America, Inc.)
- Tested
- Albumin infusion (25% albumin) (drug), Normal Saline (0.9% NaCl) (drug)
- Dates
- Started 2025-02-28; completion 2027-03
- Results posted
- Not yet
A small, pilot proof-of-concept placebo-controlled trial to explore the effects of albumin on diuresis in patients with cirrhosis, ascites and lower extremity edema. We will additionally investigate albumin's effect on preventing neurohumoral activation, and acute kidney injury after diuresis.
From ClinicalTrials.gov, last updated 2025-03-11. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Grifols Shared Services North America, Inc. reported $1,324 in research payments for this study in 2025 (1 payments).
Products named: Albutein
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- West Haven VA Medical Center $1,324
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.